Cidara Therapeutics, Inc. Forecast, price target & analysts
Cidara Therapeutics, Inc. Target price 2024 - Analyst rating & recommendation
Cidara Therapeutics, Inc. Classifications & Recommendation:
Cidara Therapeutics, Inc. Target price
| Target price | $72.50 |
| Course | $11.94 |
| Price potential |
507.20%
register free of charge
|
| Number of estimates | 2 |
|
2 Analysts have issued a price target Cidara Therapeutics, Inc. 2025 .
The average Cidara Therapeutics, Inc. target price is $72.50.
This is
507.20%
register free of charge
$120.00
905.03%
register free of charge
$25.00
109.38%
register free of charge
|
|
| A rating was issued by 2 analysts: 2 Analysts recommend Cidara Therapeutics, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst estimates: Analysts believe that the Cidara Therapeutics, Inc. share has an average upside potential 2025 of
507.20%
register free of charge
|
Sales and margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Turnover Million $ | 63.91 | 26.47 |
| 0.59% | 58.58% | |
| Net margin | -37.46% | -212.00% |
| 1,128.19% | 465.95% |
3 Analysts have issued a sales forecast Cidara Therapeutics, Inc. 2024 . The average Cidara Therapeutics, Inc. sales estimate is
This results in the following potential growth figures:
3 Cidara Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Cidara Therapeutics, Inc. net profit estimate is
This results in the following potential growth figures and future net margins:
Earnings per share, P/E ratio and EV/sales forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Earnings per share $ | -5.25 | -12.31 |
| 1,120.93% | 134.48% | |
| P/E ratio | negative | |
| EV/Sales | 1.14 |
3 Analysts have issued a Cidara Therapeutics, Inc. forecast for earnings per share. The average Cidara Therapeutics, Inc. <a href=/blog/eps>EPS is
This results in the following potential growth figures and future valuations:
Based on analysts' sales estimates for 2024, the Cidara Therapeutics, Inc. share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of
This results in the following potential growth figures and future valuations:
Cidara Therapeutics, Inc....
Discover more stocks with a high price target
Register for free
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.
